Mass General Brigham
Health Plan

Aphexda (motixafortide)
Effective 11/01/2024

Plan	☐ MassHealth UPPL ☒Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☐ Pharmacy Benefit ☒ Medical Benefit		
Specialty Limitations	N/A		
Contact Information	**Medical and Specialty Medications** All Plans | Phone: 877-519-1908 | Fax: 855-540-3693		
	Non-Specialty Medications All Plans | Phone: 800-711-4555 | Fax: 844-403-1029		
Exceptions	N/A		

Overview
Aphexda (motixafortide) is a hematopoietic stem cell mobilizer that is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Aphexda is initiated after filgrastim has been administered daily for four days. Aphexda should be administered 10-14 hours before initiating apheresis. A second dose of Aphexda can be administered 10-14 hours before a third apheresis.

Coverage Guidelines
Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance program
OR
Authorization may be granted if the member meets all the following diagnosis-specific criteria and documentation has been submitted:

1. Member has a diagnosis of multiple myeloma
2. Member is 18 years of age or older
3. Aphexda is being used to mobilize hematopoietic stem cells for autologous transplantation
4. Member has been approved by the Plan for autologous hematopoietic stem cell transplant
5. Aphexda will be used in conjunction with a granulocyte colony stimulating factor (G-CSF)
6. Member meets ONE of the following:
    a. Member has had in inadequate response, adverse reaction, or contraindication to plerixafor
    b. Prescriber submits documentation of a clinical rationale why plerixafor is not clinically appropriate for the member

Continuation of Therapy

1. Requests for reauthorization must meet initial criteria.

Limitations

1. Initial and reauthorization approvals will be granted for three months.

References

1. Aphexda (motixafortide) [prescribing information]. Waltham, MA: BioLineRx USA Inc; September 2023.
2. Crees ZD, Rettig MP, DiPersio JF. Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. *Ther Adv Hematol*. 2023(a);14:1-13. doi: 10.1177/20406207231174304.
3. Crees ZD, Rettig MP, Jayasinghe RG, et al (b). Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. *Nat Med*. 2023(b);29(4):869-879. doi: 10.1038/s41591-023-02273-z.
4. Crees ZD, Stockerl-Goldstein K, Vainstein A, et al. GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma. *Future Oncol*. 2019;15(31):3555-3563. doi: 10.2217/fon-2019-0380.
5. DiPersio JF, Stadtmauer EA, Nadamanee A, et al, for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. *Blood*. 2009;113(23):5720-5726. doi: 10.1182/blood-2008-08-174946.
6. Duong HK, Savani BN, Copelan E, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2014;20(9):1262-1273. doi: 10.1016/j.bbmt.2014.05.003.
7. Food and Drug Administration (FDA). Aphexda integrated review. FDA Web site. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217159Orig1s000IntegratedR.pdf. September 21, 2023. Accessed November 1, 2023.
8. Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. *Biol Blood Marrow Transplant*. 2014;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013.
9. Micallef IN, Stiff PJ, Nademanee AP, et al. Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: long-term follow-up report. *Biol Blood Marrow Transplant*. 2018;24(6):1187-1195. doi: 10.1016/j.bbmt.2018.01.039.
10. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. *J Clin Oncol*. 2019;37(14):1228-1263. doi: 10.1200/JCO.18.02096.
11. Mozobil [package insert], Cambridge, MA: Genzyme; September 2023.
12. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology – Hematopoietic Cell Transplantation (HCT) v3.2023. October 9, 2023(b). NCCN Web site. https://www.nccn.org/professionals/physician_gls/pdf/hct.pdf. Accessed November 1, 2023.
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology – Multiple Myeloma v2.2024. November 1, 2023(a). NCCN Web site. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed November 1, 2023.

14. Shah D. Multiple Myeloma. Medscape Web site. Updated September 13, 2023. https://emedicine.medscape.com/article/204369-overview. Accessed October 11, 2023.
15. Shah N, Callander N, Ganguly S, et al, for the American Society for Blood and Marrow Transplantation. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015;21(7):1155-1166. doi: 10.1016/j.bbmt.2015.03.002.
16. Shaughnessy P. Pushing the limits of successful mobilization of autologous hematopoietic stem cells. *Transplant Cell Ther*. 2022;28(11):721-722. doi: 10.1016/j.jtct.2022.10.001.
17. Surveillance, Epidemiology, and End Results program (SEER). Cancer stat facts: Myeloma. SEER Web site. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed November 1, 2023.

Review History

09/11/2024 – Reviewed at September P&T. Effective 11/01/2024.